高尔基体蛋白73(GP73)对慢性肝病的诊断价值

马杨青; 范海纳; 孙鑫; 刘成海

doi:10.3969/j.issn.1001-5256.2023.08.035

高尔基体蛋白73(GP73)对慢性肝病的诊断价值

DOI: 10.3969/j.issn.1001-5256.2023.08.035

马杨青¹,
范海纳¹,
孙鑫^{1, 2},
刘成海^{1, 2, 3, , ,}

1.
上海中医药大学附属曙光医院肝病研究所，上海 201203
2.
上海市中医临床重点实验室，上海 201203
3.
肝肾疾病病证教育部重点实验室，上海 201203

基金项目:

国家自然科学基金 (81730109);

国家自然科学基金 (82274305);

上海市临床重点专科建设项目 (shslczdzk01201);

上海市科学技术委员会启明星计划扬帆专项 (22YF1449300);

上海中医药大学预算内项目 (2021LK081)

利益冲突声明：本文不存在任何利益冲突。

作者贡献声明：马杨青负责数据收集、撰写论文；范海纳、孙鑫参与论文修改；刘成海负责拟定写作思路，指导撰写文章并最后定稿。

详细信息

通信作者:
刘成海，chenghailiu@hotmail.com (ORCID: 0000-0002-1696-6008)

计量
- 文章访问数: 389
- HTML全文浏览量: 143
- PDF下载量: 28
- 被引次数: 0
出版历程
- 收稿日期: 2022-11-08
- 录用日期: 2022-12-08
- 出版日期: 2023-08-20

Role of Golgi protein 73(GP73) in diagnosis of chronic liver diseases

Yangqing MA¹,
Haina FAN¹,
Xin SUN^{1, 2},
Chenghai LIU^{1, 2, 3
, ,
,}

1.
Institute of Liver Diseases, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China
2.
Shanghai Key Laboratory of Traditional Chinese Clinical Medicine, Shanghai 201203, China
3.
Key Laboratory of Liver and Kidney Diseases, Ministry of Education, Shanghai 201203, China

Research funding:

National Natural Science Foundation of China (81730109);

National Natural Science Foundation of China (82274305);

Shanghai Key Specialty of Traditional Chinese Clinical Medicine (shslczdzk01201);

Shanghai Science and Technology Commission (22YF1449300);

Shanghai University of TCM Budget Project (2021LK081)

More Information

Corresponding author: LIU Chenghai, chenghailiu@hotmail.com (0000-0002-1696-6008)

摘要

摘要: 早期诊断并准确评估肝脏炎症和纤维化程度对慢性肝病的治疗干预及预后尤为重要。本文通过回顾高尔基体蛋白73(GP73)与肝癌、肝纤维化及肝脏炎症的诊断、预后方面的研究，归纳总结了目前GP73对于慢性肝病的诊断效能。分析表明除了与肝癌有关外，GP73与肝纤维化程度及预后密切相关，也可较好地反映肝脏炎症损伤。GP73与其他血清标志物联合，可提高慢性肝病的无创诊断效能。
- 肝疾病 /
- 高尔基体基质蛋白质类 /
- 诊断
Abstract: Early diagnosis and accurate assessment of liver inflammation and fibrosis is particularly important for the therapeutic intervention and prognosis of chronic liver diseases. This article summarizes the diagnostic efficacy of Golgi protein 73 (GP73) for chronic liver diseases by reviewing related clinical studies on GP73 and the diagnosis and prognosis of liver cancer, liver fibrosis, and liver inflammation. The analysis shows that besides liver cancer, GP73 is closely associated with the degree of liver fibrosis and prognosis and can better reflect liver inflammatory damage. GP73 combined with other serum markers can improve the noninvasive diagnosis of chronic liver diseases.
- Liver Diseases /
- Golgi Matrix Proteins /
- Diagnosis

HTML全文

表 1 血清GP73用于HCC诊断的研究报道

Table 1. Clinical researches of serum GP73 for HCC diagnosis

第一作者	年份	研究对象	例数	GP73
第一作者	年份	研究对象	例数	敏感度(%)	特异度(%)	阳性预测值(%)	阴性预测值(%)	AUC	cut-off值
Marrero等^[18]	2005	HCC vs 肝硬化	144	69.00	86.00			0.790	10个相对单位
Marrero等^[18]	2005	早期HCC vs 肝硬化	69	62.00	88.00			0.770	10个相对单位
包永星等^[21]	2013	早期HCC vs 肝硬化	40	72.50	70.40			0.749	178.2 μg/L
Zhang等^[25]	2015	AFP阴性的HCC	50	66.00	96.20
Mao等^[20]	2010	HCC vs 非HCC	789	74.60	97.40	82.70	91.20	0.940	8.5个相对单位
Liu等^[29]	2017	HCC vs 非肝硬化	1 102					0.834
		HCC vs 肝硬化	1 102					0.613
		有无肝硬化背景的HCC	197					0.527
Dong等^[27]	2017	HCC vs 肝硬化	186	27.79	77.96			0.510	43.95 ng/mL
Gatselis等^[26]	2020	HCC vs 非HCC	130	56.00	59.00	26.00	83.00	0.623	20个相对单位

下载: 导出CSV

表 2 血清GP73用于肝纤维化与肝硬化诊断的研究报道

Table 2. Clinical researches of serum GP73 for the diagnosis of liver fibrosis and cirrhosis

第一作者	年份	研究对象	例数	GP73
第一作者	年份	研究对象	例数	敏感度(%)	特异度(%)	阳性预测值(%)	阴性预测值(%)	AUC	cut-off值
Gatselis等^[26]	2020	肝硬化	450	59.00	95.00			0.909	20个单位
Xu等^[34]	2015	肝硬化	250	79.20	80.00			0.830	138.20 ng/mL
		失代偿期肝硬化	200	66.50	66.00			0.710	186.20 ng/mL
鲁凤民等^[33]	2018	代偿期肝硬化	2 203	79.97	92.43			0.899
		代偿性肝硬化	1 230	79.90	87.38	85.92	81.76	0.873	72.53 ng/mL
		CHB代偿期肝硬化	891					0.880
		CHC代偿期肝硬化	446					0.926
		AILD代偿期肝硬化	337					0.885
		NAFLD代偿期肝硬化	143					0.962
		其他原因代偿期肝硬化	386					0.935
		病毒性肝炎肝纤维化(F≥2)	200	57.50	88.73	93.50	42.60	0.772	68.84 ng/mL
		AILD肝纤维化(F≥2)	143	74.13	92.00	98.10	38.30	0.855	54.33 ng/mL
		NAFLD肝纤维化(F≥2)	58	76.27	88.10	81.80	84.10	0.897	59.17 ng/mL
王鹏飞等^[32]	2022	HCV代偿期肝硬化	145	84.92	91.03			0.923	73.56 ng/mL

下载: 导出CSV

表 3 血清GP73用于肝炎诊断的研究报道

Table 3. Clinical researches of serum GP73 for hepatic inflammation diagnosis

第一作者	年份	疾病类型	例数	GP73
第一作者	年份	疾病类型	例数	敏感度(%)	特异度(%)	阳性预测值(%)	阴性预测值(%)	AUC	cut-off值
Wei等^[35]	2019	CHB	220	43.59	97.18			0.806	85.7 ng/mL
Yao等^[30]	2019	CHB(ALT＜40 U/L)	367	80.41	68.79	74.30	75.80	0.803	79.79 ng/mL
姚明解等^[36]	2018	CHB(G≥2)	477	70.61	71.98			0.774	77.88 ng/mL
冯志刚等^[37]	2015	酒精性肝病	119	71.40	95.20	90.40	83.90
Wang等^[38]	2020	NASH(G≥2)	76	44.74	92.80	79.07	73.42	0.742	94.57 ng/mL
Li等^[39]	2021	NASH	46					0.830
Yao等^[40]	2022	AIH(G≥2)	63	77.78	90.91	98.00	41.70	0.828	54.52 ng/mL
		PBC(G≥2)	78	74.36	75.00	93.50	37.50	0.797	48.19 ng/mL

下载: 导出CSV

参考文献(40)

[1]	Chinese Society of Hepatology, Chinese Medical Association; Chinese Society of Gastroenterology, Chinese Medical Association; Chinese Society of Infectious Diseases, Chinese Medical Association. Consensus on the diagnosis and therapy of hepatic fibrosis(2019)[J]. J Clin Hepatol, 2019, 35(10): 2163-2172. DOI: 10.3969/j.issn.1001-5256.2019.10.007. 中华医学会肝病学分会, 中华医学会消化病学分会, 中华医学会感染病学分会. 肝纤维化诊断及治疗共识(2019年)[J]. 临床肝胆病杂志, 2019, 35(10): 2163-2172. DOI: 10.3969/j.issn.1001-5256.2019.10.007.
[2]	KLADNEY RD, BULLA GA, GUO L, et al. GP73, a novel Golgi-localized protein upregulated by viral infection[J]. Gene, 2000, 249(1-2): 53-65. DOI: 10.1016/s0378-1119(00)00136-0.
[3]	LIU XY, FAN ZJ, ZHOU C, et al. Expression and clinical significance of Golgi protein 73 and Ki-67 in gallbladder carcinoma[J]. J Prac Med, 2017, 33(1): 47-50. DOI: 10.3969/j.issn.1006-5725.2017.01.013. 刘星雨, 范正军, 周闯, 等. 高尔基体蛋白GP73和Ki-67在胆囊癌中的表达及临床意义[J]. 实用医学杂志, 2017, 33(1): 47-50. DOI: 10.3969/j.issn.1006-5725.2017.01.013.
[4]	KRISTIANSEN G, FRITZSCHE FR, WASSERMANN K, et al. GOLPH2 protein expression as a novel tissue biomarker for prostate cancer: implications for tissue-based diagnostics[J]. Br J Cancer, 2008, 99(6): 939-948. DOI: 10.1038/sj.bjc.6604614.
[5]	LIANG R, LIU Z, PIAO X, et al. Research progress on GP73 in malignant tumors[J]. Onco Targets Ther, 2018, 11: 7417-7421. DOI: 10.2147/OTT.S181239.
[6]	XIA Y, ZHANG Y, SHEN M, et al. Golgi protein 73 and its diagnostic value in liver diseases[J]. Cell Prolif, 2019, 52(2): e12538. DOI: 10.1111/cpr.12538.
[7]	KLADNEY RD, CUI X, BULLA GA, et al. Expression of GP73, a resident Golgi membrane protein, in viral and nonviral liver disease[J]. Hepatology, 2002, 35(6): 1431-1440. DOI: 10.1053/jhep.2002.32525.
[8]	YE QH, ZHU WW, ZHANG JB, et al. GOLM1 modulates EGFR/RTK cell-surface recycling to drive hepatocellular carcinoma metastasis[J]. Cancer Cell, 2016, 30(3): 444-458. DOI: 10.1016/j.ccell.2016.07.017.
[9]	IFTIKHAR R, KLADNEY RD, HAVLIOGLU N, et al. Disease- and cell-specific expression of GP73 in human liver disease[J]. Am J Gastroenterol, 2004, 99(6): 1087-1095. DOI: 10.1111/j.1572-0241.2004.30572.x.
[10]	MANNAERTS I, SCHROYEN B, VERHULST S, et al. Gene expression profiling of early hepatic stellate cell activation reveals a role for Igfbp3 in cell migration[J]. PLoS One, 2013, 8(12): e84071. DOI: 10.1371/journal.pone.0084071.
[11]	WANG S, JUNG Y, HYUN J, et al. RNA binding proteins control transdifferentiation of hepatic stellate cells into myofibroblasts[J]. Cell Physiol Biochem, 2018, 48(3): 1215-1229. DOI: 10.1159/000491987.
[12]	MA LY, ZHEN YN, LUO YP, et al. Expression and mechanism of gp73 in liver tissure of mouse liver fibrosis[J]. Basic Clin Med, 2020, 40(6): 771-776. DOI: 10.16352/j.issn.1001-6325.2020.06.005. 马玲玉, 甄一宁, 罗云萍, 等. gp73在小鼠肝纤维化肝组织中的表达及机制[J]. 基础医学与临床, 2020, 40(6): 771-776. DOI: 10.16352/j.issn.1001-6325.2020.06.005.
[13]	YAO M, WANG L, LEUNG P, et al. The clinical significance of GP73 in immunologically mediated chronic liver diseases: experimental data and literature review[J]. Clin Rev Allergy Immunol, 2018, 54(2): 282-294. DOI: 10.1007/s12016-017-8655-y.
[14]	WAN LM, GAO Q, DENG YQ, et al. GP73 is a glucogenic hormone contributing to SARS-CoV-2-induced hyperglycemia[J]. Nat Metab, 2022, 4(1): 29-43. DOI: 10.1038/s42255-021-00508-2.
[15]	YANG X, WU F, CHEN J, et al. GP73 regulates Hepatic Steatosis by enhancing SCAP-SREBPs interaction[J]. Sci Rep, 2017, 7(1): 14932. DOI: 10.1038/s41598-017-06500-9.
[16]	General Office of National Health Commission. Standard for diagnosis and treatment of primary liver cancer (2022 edition)[J]. J Clin Hepatol, 2022, 38(2): 288-303. DOI: 10.3969/j.issn.1001-5256.2022.02.009. 国家卫生健康委办公厅. 原发性肝癌诊疗指南(2022年版)[J]. 临床肝胆病杂志, 2022, 38(2): 288-303. DOI: 10.3969/j.issn.1001-5256.2022.02.009.
[17]	SONG PP, XIA JF, INAGAKI Y, et al. Controversies regarding and perspectives on clinical utility of biomarkers in hepatocellular carcinoma[J]. World J Gastroenterol, 2016, 22(1): 262-274. DOI: 10.3748/wjg.v22.i1.262.
[18]	MARRERO JA, ROMANO PR, NIKOLAEVA O, et al. GP73, a resident Golgi glycoprotein, is a novel serum marker for hepatocellular carcinoma[J]. J Hepatol, 2005, 43(6): 1007-1012. DOI: 10.1016/j.jhep.2005.05.028.
[19]	BLOCK TM, COMUNALE MA, LOWMAN M, et al. Use of targeted glycoproteomics to identify serum glycoproteins that correlate with liver cancer in woodchucks and humans[J]. Proc Natl Acad Sci U S A, 2005, 102(3): 779-784. DOI: 10.1073/pnas.0408928102.
[20]	MAO Y, YANG H, XU H, et al. Golgi protein 73 (GOLPH2) is a valuable serum marker for hepatocellular carcinoma[J]. Gut, 2010, 59(12): 1687-1693. DOI: 10.1136/gut.2010.214916.
[21]	BAO YX, YANG Y, ZHAO HR, et al. Clinical significance and diagnostic value of Golgi-protein 73 in patients with early-stage primary hepatocellular carcinoma[J]. Chin J Oncol, 2013, 35(7): 505-508. DOI: 10.3760/cma.j.issn.0253-3766.2013.07.006. 包永星, 杨颖, 赵化荣, 等. 高尔基体蛋白73对早期肝癌的诊断价值及临床意义[J]. 中华肿瘤杂志, 2013, 35(7): 505-508. DOI: 10.3760/cma.j.issn.0253-3766.2013.07.006.
[22]	KE MY, WU XN, ZHANG Y, et al. Serum GP73 predicts posthepatectomy outcomes in patients with hepatocellular carcinoma[J]. J Transl Med, 2019, 17(1): 140. DOI: 10.1186/s12967-019-1889-0.
[23]	DONG MC, BAI J, LIU HS, et al. The clinical application of serum GPC3, DCP, GP73, and AFP in hepatocellular carcinoma[J]. Labeled Immunoassays Clin Med, 2022, 29(7): 1142-1147. DOI: 10.11748/bjmy.issn.1006-1703.2022.07.013. 董美衬, 白晶, 刘海顺, 等. 血清GPC3、DCP、GP73及AFP联合检测在原发性肝癌的诊断价值[J]. 标记免疫分析与临床, 2022, 29(7): 1142-1147. DOI: 10.11748/bjmy.issn.1006-1703.2022.07.013.
[24]	CUI Q, DONG YE, HUO YL, et al. Simultaneous detection of serum AFP, GP73, SF and DCP in the diagnosis of primary liver cancer[J]. J China Med Univ, 2019, 48(5): 434-436. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGYK201905013.htm 崔琦, 董延娥, 霍云龙, 等. 血清AFP、GP73、SF、DCP联合检测在原发性肝癌诊断中的应用[J]. 中国医科大学学报, 2019, 48(5): 434-436. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGYK201905013.htm
[25]	ZHANG Z, ZHANG Y, WANG Y, et al. Alpha-fetoprotein-L3 and Golgi protein 73 may serve as candidate biomarkers for diagnosing alpha-fetoprotein-negative hepatocellular carcinoma[J]. Onco Targets Ther, 2016, 9: 123-129. DOI: 10.2147/OTT.S90732.
[26]	GATSELIS NK, TORNAI T, SHUMS Z, et al. Golgi protein-73: A biomarker for assessing cirrhosis and prognosis of liver disease patients[J]. World J Gastroenterol, 2020, 26(34): 5130-5145. DOI: 10.3748/wjg.v26.i34.5130.
[27]	DONG M, CHEN ZH, LI X, et al. Serum Golgi protein 73 is a prognostic rather than diagnostic marker in hepatocellular carcinoma[J]. Oncol Lett, 2017, 14(5): 6277-6284. DOI: 10.3892/ol.2017.6938.
[28]	LU FM. Serological diagnosis of hepatocellular carcinoma: challenges and opportunities[J]. J Clin Hepatol, 2017, 33(7): 1262-1265. DOI: 10.3969/j.issn.1001-5256.2017.07.011. 鲁凤民. 肝细胞癌的血清学诊断——挑战与希望同在[J]. 临床肝胆病杂志, 2017, 33(7): 1262-1265. DOI: 10.3969/j.issn.1001-5256.2017.07.011.
[29]	LIU TH, YAO MJ, LIU SH, et al. Serum Golgi protein 73 is not a suitable diagnostic marker for hepatocellular carcinoma[J]. Oncotarget, 2017, 8(10): 16498-16506. DOI: 10.18632/oncotarget.14954.
[30]	YAO M, WANG L, YOU H, et al. Serum GP73 combined AST and GGT reflects moderate to severe liver inflammation in chronic hepatitis B[J]. Clin Chim Acta, 2019, 493: 92-97. DOI: 10.1016/j.cca.2019.02.019.
[31]	LIU L, WANG J, FENG J, et al. Serum Golgi protein 73 is a marker comparable to APRI for diagnosing significant fibrosis in children with liver disease[J]. Sci Rep, 2018, 8(1): 16730. DOI: 10.1038/s41598-018-34714-y.
[32]	WANG PF, LIU SH, QIAN XJ, et al. The diagnostic potential of Golgi protein 73 for cirrhosis in patients with chronic hepatitis C[J]. Chin J Hepatol, 2022, 30(8): 879-884. DOI: 10.3760/cma.j.cn501113-20200415-00186. 王鹏飞, 刘树红, 钱相君, 等. 血清高尔基体蛋白73对丙型肝炎肝硬化的诊断价值研究[J]. 中华肝脏病杂志, 2022, 30(8): 879-884. DOI: 10.3760/cma.j.cn501113-20200415-00186.
[33]	LIU FM, ZHANG Y. Diagnostic application of serum GP73 and the relevant mechanism in the diagnosis of liver cirrhosis[J]. Chin J Hepatol, 2018, 26(5): 321-324. DOI: 10.3760/cma.j.issn.1007-3418.2018.05.001. 鲁凤民, 张芸. 血清高尔基体糖蛋白73在肝硬化诊断中的应用及其相关机制[J]. 中华肝脏病杂志, 2018, 26(5): 321-324. DOI: 10.3760/cma.j.issn.1007-3418.2018.05.001.
[34]	XU Z, LIU L, PAN X, et al. Serum Golgi protein 73 (GP73) is a diagnostic and prognostic marker of chronic HBV liver disease[J]. Medicine (Baltimore), 2015, 94(12): e659. DOI: 10.1097/MD.0000000000000659.
[35]	WEI M, XU Z, PAN X, et al. Serum GP73 - an additional biochemical marker for liver inflammation in chronic HBV infected patients with normal or slightly raised ALT[J]. Sci Rep, 2019, 9(1): 1170. DOI: 10.1038/s41598-018-36480-3.
[36]	YAO MJ, WANG LJ, GUAN GW, et al. Value of serum Golgi protein 73 in assisting the diagnosis of moderate or severe liver injury in patients with chronic hepatitis B[J]. J Clin Hepatol, 2018, 34(4): 755-759. DOI: 10.3969/j.issn.1001-5256.2018.04.012. 姚明解, 王雷婕, 关贵文, 等. 血清高尔基体蛋白73在辅助诊断慢性乙型肝炎患者中度以上肝损伤中的应用[J]. 临床肝胆病杂志, 2018, 34(4): 755-759. DOI: 10.3969/j.issn.1001-5256.2018.04.012.
[37]	FENG ZG, CEN XH, YUN JM, et al. Diagnostic value of GP73 in alcoholic liver disease[J]. Int J Lab Med, 2015, 36(15): 2214-2215, 2217. DOI: 10.3969/j.issn.1673-4130.2015.15.037. 冯志刚, 岑晓红, 云俊木, 等. GP73在酒精性肝病中的临床意义[J]. 国际检验医学杂志, 2015, 36(15): 2214-2215, 2217. DOI: 10.3969/j.issn.1673-4130.2015.15.037.
[38]	WANG L, YAO M, LIU S, et al. Serum golgi protein 73 as a potential biomarker for hepatic necroinflammation in population with nonalcoholic steatohepatitis[J]. Dis Markers, 2020, 2020: 6036904. DOI: 10.1155/2020/6036904.
[39]	LI Y, YANG Y, LI Y, et al. Use of GP73 in the diagnosis of non-alcoholic steatohepatitis and the staging of hepatic fibrosis[J]. J Int Med Res, 2021, 49(11): 3000605211055378. DOI: 10.1177/03000605211055378.
[40]	YAO M, WANG L, WANG J, et al. Diagnostic value of serum golgi protein 73 for liver inflammation in patients with autoimmune hepatitis and primary biliary cholangitis[J]. Dis Markers, 2022, 2022: 4253566. DOI: 10.1155/2022/4253566.